An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
鞘内酶替代治疗粘多糖贮积症 I 型认知衰退的推广研究
基本信息
- 批准号:9146688
- 负责人:
- 金额:$ 4.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:3 year oldAddressAdverse effectsAdverse eventAffectAgeAreaBiochemicalBlood - brain barrier anatomyBrainCanis familiarisCentral Nervous System AgentsCentral Nervous System DiseasesCerebrospinal FluidChildClinicalCognitionCognitiveCoupledDataDementiaDevelopmentDiffusionDiffusion Magnetic Resonance ImagingDiseaseEnzymesFiberFundingGlycosaminoglycansGoalsHeadacheHearingHematopoietic Stem Cell TransplantationHumanHydrocephalusImmune responseImpaired cognitionInheritedInstructionIntelligence TestsIntravenousL-IduronidaseLanguage DevelopmentLearningLongevityLongitudinal StudiesLysosomal Storage DiseasesMagnetic Resonance ImagingMeasuresMemoryMemory LossMental RetardationMorphologyMucopolysaccharidosis INamesNeuraxisNeurologicNeurologic ExaminationNeuropsychological TestsOutcomeOutcome MeasureParticipantPatientsPhasePilot ProjectsProteinsRandomizedRecombinantsReportingSafetySchoolsSeveritiesStructureStudy SubjectSymptomsTeenagersTestingTimeTransplantationVisionVisitWalkingclinical carecognitive developmentdrug developmentemerging adultfallsfollow-upinnovationnervous system disorderneurobehavioralneuropsychologicalopen labelpost-marketpre-clinical researchpreventprospectivescreeningspinal cord compressionsymptom treatmenttreatment effectwhite matter
项目摘要
"Mucopolysaccharidosis I (MPS I) is an inherited lysosomal storage disease due to deficiency of alpha-Liduronidase.
Recombinant human alpha-L-iduronidase (rhIDU) is available as laronidase (trade name
"Aldurazyme") for intravenous delivery to treat physical disease due to MPS I. While partially effective for
physical disease, intravenous rhIDU does not treat neurological symptoms of MPS I, because the blood-brain
barrier prevents the bulk of the administered protein from entering the central nervous system (CNS).
Patients with MPS I suffer from progressive neurological disease, including cognitive decline and dementia,
as well as spinal cord compression, hearing and vision problems, hydrocephalus and headaches. Our
preclinical research has found that intrathecal (IT) administration of rhIDU can disperse throughout the
neuraxis, reach deep brain structures and remove brain lysosomal storage in MPS I dogs. We have treated
a small number of MPS I subjects with IT rhIDU for disease-related spinal cord compression and have found
no significant safety concerns for this approach. Currently, we are conducting a 2-year randomized study of
IT rhIDU for cognitive decline in MPS I patients, which was funded as a pilot project by the LDN
(NCT008523580). This new project would permit a five-year extension study for participants in the pilot
project, which would allow us to collect long-term data on safety and efficacy. The primary safety outcome
measure will be the rate and severity of treatment-related adverse effects. The primary efficacy outcome
measure will be the mean intra-subject change in memory score between baseline and the subject's final
visit. Other important efficacy measures are changes in scores of tests of other neuropsychological domains
and changes in 3 Tesla brain magnetic resonance imaging (MRI) parameters, such as volumes, morphology,
diffusion abnormalities and white matter fiber tracking. Currently, there are no treatment options for the brain
in MPS I patients, except for the youngest, most severely affected patients, who may be considered for
hematopoietic stem cell transplantation. If successful, intrathecal rhIDU would bring major innovation to the
clinical care of MPS I patients.
粘多糖沉积症I(MPS I)是一种由于α-利杜糖醛酸酶缺乏引起的遗传性溶酶体储存病。
重组人α-L-艾杜糖醛酸酶(rhIDU)可作为laronidase(商品名
“Aldurazyme”)静脉给药,治疗MPS I引起的身体疾病。虽然部分有效,
身体疾病,静脉注射rhIDU不能治疗MPS I的神经系统症状,因为血脑
屏障防止大部分施用的蛋白质进入中枢神经系统(CNS)。
患有MPS I的患者患有进行性神经系统疾病,包括认知下降和痴呆,
以及脊髓压迫、听力和视力问题、脑积水和头痛。我们
临床前研究发现,rhIDU鞘内(IT)给药可分散在整个
神经轴,到达深部脑结构并清除MPS I犬的脑溶酶体蓄积。我们对待
少数接受IT rhIDU治疗疾病相关脊髓压迫的MPS I受试者,并发现
这种方法没有显著的安全性问题。目前,我们正在进行一项为期2年的随机研究,
IT rhIDU治疗MPS I患者的认知下降,由LDN作为试点项目资助
(NCT008523580)。这一新项目将允许对试点参与者进行为期五年的扩展研究
这将使我们能够收集有关安全性和有效性的长期数据。主要安全性结局
衡量标准是治疗相关不良反应的发生率和严重程度。主要疗效结局
测量将是基线和受试者最终记忆评分之间的受试者内平均变化
访问其他重要的功效指标是其他神经心理学领域测试评分的变化
以及3特斯拉脑磁共振成像(MRI)参数的变化,例如体积,形态,
弥散异常和白色纤维追踪。目前,还没有针对大脑的治疗方案
在MPS I患者中,除最年轻、受影响最严重的患者外,
造血干细胞移植如果成功,rhIDU鞘内注射将为
MPS I患者的临床护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Agnes Huang Chen其他文献
Agnes Huang Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Agnes Huang Chen', 18)}}的其他基金
An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
鞘内酶替代治疗粘多糖贮积症 I 型认知衰退的推广研究
- 批准号:
8907060 - 财政年份:
- 资助金额:
$ 4.5万 - 项目类别:
An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
鞘内酶替代治疗粘多糖贮积症 I 型认知衰退的推广研究
- 批准号:
9557579 - 财政年份:
- 资助金额:
$ 4.5万 - 项目类别:
An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
鞘内酶替代治疗粘多糖贮积症 I 型认知衰退的推广研究
- 批准号:
8934174 - 财政年份:
- 资助金额:
$ 4.5万 - 项目类别:
An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
鞘内酶替代治疗粘多糖贮积症 I 型认知衰退的推广研究
- 批准号:
9338314 - 财政年份:
- 资助金额:
$ 4.5万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 4.5万 - 项目类别:
Research Grant